Cho Hansam, Jang Yuyeon, Park Ki-Hoon, Choi Hanul, Nowakowska Aleksandra, Lee Hee-Jung, Kim Minjee, Kang Min-Hee, Kim Jin-Hoi, Shin Ha Youn, Oh Yu-Kyoung, Kim Young Bong
KR BioTech, Seoul, Republic of Korea.
Department of Bio-industrial Technologies, Konkuk University, Seoul, Republic of Korea.
NPJ Vaccines. 2021 Mar 19;6(1):37. doi: 10.1038/s41541-021-00303-w.
Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.
在此，我们报告一种基于重组杆状病毒载体的DNA疫苗系统，用于对抗中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒2（SARS-CoV2）。构建了一种表达人内源性逆转录病毒包膜基因（AcHERV）的非复制型重组杆状病毒，作为将基因递送至人细胞的DNA疫苗载体。对于MERS-CoV疫苗构建，将编码MERS-CoV S全长、S1亚基或受体结合域（RBD）的DNA插入AcHERV基因组。对于COVID-19疫苗构建，将编码SARS-CoV2 S全长或S1或MERS-CoV NTD结构域融合的SARS-CoV2 RBD的DNA插入AcHERV基因组。AcHERV-DNA疫苗在动物模型中诱导出高水平的体液免疫和细胞介导免疫。在攻毒试验中，两次免疫的AcHERV-MERS-S1和AcHERV-COVID19-S分别对MERS-CoV和SARS-CoV2表现出完全保护作用。与AcHERV-MERS疫苗不同，AcHERV-COVID19-S对SARS-CoV2攻毒提供了最大程度的保护。这些结果支持AcHERV-MERS或AcHERV-COVID19疫苗在预防病毒感染大流行传播方面的可行性。
